atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option.
atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a 'Buy' rating from Jefferies analysts as the company's pipeline of mental health therapies enters a catalyst-rich period. “atai's pipeline of psychedelics (and non-psychedelics) has the potential to safely, profoundly, and durably treat tough $1 billion-plus in central nervous systems indications,” analysts wrote in a note to clients.
atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable securities, and committed term loan funding available which is expected to fund its operations into 2026. In addition to announcing its second quarter financial results, atai on Tuesday unveiled positive preliminary Phase 1b trial results for VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface.
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Dirt-Cheap Drug Developers With Blockbuster Potential
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn't a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy).
3 Psychedelic Stocks to Ride to the Moon and Beyond
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.
atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech's Phase 1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. The company owned a 35.5% stake in Beckley Psytech.
atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech's Phase1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. Beckley Psytech, a private clinical-stage biopharmaceutical company in which atai holds a 35.5% ownership stake, reported that initial data from Phase 1 single ascending dose study in healthy participants showed that ELE-101 was well-tolerated, with no serious or severe adverse events reported, and demonstrated a dose-proportional profile, which leads to reduced variability between patients when compared to oral psilocybin.
atai Life Sciences poised for success with rigorous clinical trials
Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical setback.” On June 4, Lykos Therapeutics brought its application for MDMA-assisted therapy for post-traumatic stress disorder before the Food and Drug Administration (FDA) Advisory Committee (AdCom).
